Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer

Inclusion Criteria:

• Patients who were diagnosed as metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma by histopathology or cytology, at least one measurable lesion conforming to RECIST 1.1 criteria.
• Disease progresses or intolerance for first-line standard treatment, including patients who relapsed or metastasized within 6 months of neoadjuvant or adjuvant therapy
• ECOG score 0-2
• Adequate organ and bone marrow function
• The expected survival time is ≥ 12 weeks
• Had normal swallowing function, without dysfunction of gastrointestinal absorption
• Willing to consent and signed the informed consent, and able comply with the planned visit, research treatment, laboratory examination and other test procedures

Exclusion Criteria:

• The patient has previously received anti-angiogenic drugs or albumin-bound paclitaxel;
• The first study drug treatment was less than 2 weeks or 5 half-lives (in terms of longer) from the last chemotherapy or 5 half-lives from the last targeted therapy
• Known to be allergic to the active ingredients or excipients in this study.
• Had other active malignant tumors within 5 years before entering the study.
• Subject with cerebral metastasis
• Have a clear history of serious and uncontrolled other disease or mental disorders;
• Other chemotherapy, targeted therapy, hormonotherapy, immunotherapy, radiotherapy or traditional Chinese medicine should be used for anti-tumor therapy
• Other situations that the researcher considers inappropriate to participate in the research.